Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478176 | 0.86 | CA1 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8148281 | 0.86 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28289517 | 0.83 | CA12 (0.54) | S1PR3CA1CA2CA12CA7 | |
| SCHEMBL13193177 | 0.83 | CA12 (0.54) | S1PR3CA1CA2CA12CA7 | |
| SCHEMBL1008899 | 0.83 | CA1 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2818982 | 0.83 | KDM4E (0.53) | S1PR3CA1CA2CA12CA7 | |
| SCHEMBL2427132 | 0.83 | CA1 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL105391 | 0.81 | ALDH1A1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4950780 | 0.81 | KDM4E (0.60) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2143380 | 0.81 | NOTUM (0.54) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106431969-B | A kind of method for preparing 2- methyl -4- formaldoxime yl benzoic acid methyl esters | 荆门医药工业技术研究院 | 2018-07-06 | — | — | CN | claimed |
| EP-4333985-B1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240262814-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-118324614-A | Synthesis method of 2-methyl-4-formaldoxime benzoic acid or derivative thereof | 珠海保税区丽珠合成制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4333985-A1 | MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117561251-A | Modulators of TREX1 | 星座制药公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| CN-112955448-B | Aromatic ring or aromatic heterocyclic compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022235725-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220127258-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2022-04-28 | — | — | US | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007025009-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| US-5607944-A | ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262814-A1 | MODULATORS OF TREX1 | CFTR, SLC10A1, CYP27A1 | S1PR3 1638/4885CA1 4609/4885CA2 3783/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | S1PR3 2702/4885CA1 4454/4885CA2 4442/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | S1PR3 2519/4885CA1 350/4885CA2 196/4885 |
| US-20220127258-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP46A1, NR1H4, CYP7A1 | S1PR3 1862/4885CA1 4834/4885CA2 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.